SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

September 22, 2022

https://www.globenewswire.com/news-release/2022/09/22/2520927/0/en/SciSparc-Ltd-and-Clearmind-Medicine-Inc-Collaboration-Yields-3rd-Patent-Application-for-the-Treating-of-Obesity-and-Metabolic-Syndromes.html

TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the Company’s collaboration with Clearmind.

Read more at globenewswire.com

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.